Modified Starch Material of Biocompatible Hemostasis

Abstract

A modified starch material is arranged for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

What is claimed is: 
     
         1 . A method of forming a starch-blood coagulation on a wounded tissue of an animal, comprising a step of applying a biocompatible modified starch which is a hemostatic powder consisting essentially of biocompatible modified starch particles having water absorbency capacity not lower than 1 times its own particle weight and a molecular weight 10,000 Daltons or more and a grain diameter of 10 to 1000 μm, wherein the hemostatic powder has an adhesiveness sufficient that the hemostatic powder forms a starch-blood coagulation upon contacting the wounded tissue when being applied directly onto the wounded tissue of the animal, wherein the biocompatible modified starch contains one or more groups of pre-gelatinized starch, acid modified starch, oxidized starch, esterified starch, and cross-linked starch, wherein the biocompatible modified starch contains at least pre-gelatinized hydroxypropyl distarch phosphate in pre-gelatinization modification. 
     
     
         2 . The method, as recited in  claim 1 , wherein the biocompatible modified starch particles have starch grains with grain diameter 30 to 500 μm, at least 95% starch grains in said hemostatic powder with a diameter 30 to 500 μm of in total, and a viscosity of a 6.67% suspension not lower than 30 mPas at 37° C. 
     
     
         3 . The method, as recited in  claim 1 , wherein the biocompatible modified starch particles are converted into a form selected from the group consisting of hemostatic powder form, hemostatic spherical form, hemostatic granule form, and hemostatic aerosol form. 
     
     
         4 . The method, as recited in  claim 2 , wherein the biocompatible modified starch particles are converted into a form selected from the group consisting of hemostatic powder form, hemostatic spherical form, hemostatic granule form, and hemostatic aerosol form. 
     
     
         5 . A method of forming a starch-blood coagulation on a wounded tissue of an animal, comprising a step of applying a biocompatible modified starch which is a hemostatic powder consisting essentially of biocompatible modified starch particles having water absorbency capacity not lower than 1 times its own particle weight and a molecular weight 10,000 Daltons or more and a grain diameter of 10 to 1000 μm, wherein the hemostatic powder has an adhesiveness sufficient that the hemostatic powder forms a starch-blood coagulation upon contacting the wounded tissue when being applied directly onto the wounded tissue of the animal, wherein the biocompatible modified starch particles have starch grains with grain diameter 30 to 500 μm, at least 95% starch grains in said hemostatic powder with a diameter 30 to 500 μm of in total, wherein the biocompatible modified starch contains one or more groups of pre-gelatinized starch, acid modified starch, oxidized starch, esterified starch, and cross-linked starch, wherein the biocompatible modified starch contains at least pre-gelatinized hydroxypropyl distarch phosphate in pre-gelatinization modification. 
     
     
         6 . The method, as recited in  claim 5 , wherein the biocompatible modified starch particles have starch grains with grain diameter 30 to 500 μm, at least 95% starch grains in said hemostatic powder with a diameter 30 to 500 μm of in total, and a viscosity of a 6.67% suspension not lower than 30 mPas at 37° C. 
     
     
         7 . The method, as recited in  claim 5 , wherein the biocompatible modified starch particles are converted into a form selected from the group consisting of hemostatic powder form, hemostatic spherical form, hemostatic granule form, and hemostatic aerosol form. 
     
     
         8 . The method, as recited in  claim 6 , wherein the biocompatible modified starch particles are converted into a form selected from the group consisting of hemostatic powder form, hemostatic spherical form, hemostatic granule form, and hemostatic aerosol form. 
     
     
         9 . A method of forming a starch-blood coagulation on a wounded tissue of an animal, comprising a step of applying a biocompatible modified starch which is a hemostatic powder consisting essentially of biocompatible modified starch particles having water absorbency capacity not lower than 1 times its own particle weight and a molecular weight 10,000 Daltons or more and a grain diameter of 10 to 1000 μm, wherein the hemostatic powder has an adhesiveness sufficient that the hemostatic powder forms a starch-blood coagulation upon contacting the wounded tissue when being applied directly onto the wounded tissue of the animal, wherein said biocompatible modified starch contains one or more groups of pre-gelatinized starch, acid modified starch, oxidized starch, esterified starch, and cross-linked starch, wherein the biocompatible modified starch contains at least one carboxymethyl starch, hydroxyethyl starch, and cationic starch in pre-gelatinization modification. 
     
     
         10 . The method, as recited in  claim 9 , wherein the biocompatible modified starch particles have starch grains with grain diameter 30 to 500 μm, at least 95% starch grains in said hemostatic powder with a diameter 30 to 500 μm of in total, and a viscosity of a 6.67% suspension not lower than 30 mPas at 37° C. 
     
     
         11 . The method, as recited in  claim 9 , wherein the biocompatible modified starch particles are converted into a form selected from the group consisting of hemostatic powder form, hemostatic spherical form, hemostatic granule form, and hemostatic aerosol form. 
     
     
         12 . The method, as recited in  claim 10 , wherein the biocompatible modified starch particles are converted into a form selected from the group consisting of hemostatic powder form, hemostatic spherical form, hemostatic granule form, and hemostatic aerosol form. 
     
     
         13 . A method of forming a starch-blood coagulation on a wounded tissue of an animal, comprising a step of applying a biocompatible modified starch which is a hemostatic powder consisting essentially of biocompatible modified starch particles having water absorbency capacity not lower than 1 times its own particle weight and a molecular weight 10,000 Daltons or more and a grain diameter of 10 to 1000 μm, wherein the hemostatic powder has an adhesiveness sufficient that the hemostatic powder forms a starch-blood coagulation upon contacting the wounded tissue when being applied directly onto the wounded tissue of the animal, wherein the biocompatible modified starch particles have starch grains with grain diameter 30 to 500 μm, at least 95% starch grains in said hemostatic powder with a diameter 30 to 500 μm of in total, wherein the biocompatible modified starch contains one or more groups of pre-gelatinized starch, acid modified starch, oxidized starch, esterified starch, and cross-linked starch, wherein the biocompatible modified starch contains at least one carboxymethyl starch, hydroxyethyl starch, and cationic starch in pre-gelatinization modification. 
     
     
         14 . The method, as recited in  claim 13 , wherein the biocompatible modified starch particles have starch grains with grain diameter 30 to 500 μm, at least 95% starch grains in said hemostatic powder with a diameter 30 to 500 μm of in total, and a viscosity of a 6.67% suspension not lower than 30 mPas at 37° C. 
     
     
         15 . The method, as recited in  claim 13 , wherein the biocompatible modified starch particles are converted into a form selected from the group consisting of hemostatic powder form, hemostatic spherical form, hemostatic granule form, and hemostatic aerosol form. 
     
     
         16 . The method, as recited in  claim 14 , wherein the biocompatible modified starch particles are converted into a form selected from the group consisting of hemostatic powder form, hemostatic spherical form, hemostatic granule form, and hemostatic aerosol form.